Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study record content with an access-denied screen. As a result, the core trial details and navigation are no longer visible, hindering user access to sponsor information, locations, eligibility criteria, and interventions.SummaryDifference19%

- Check21 days agoChange DetectedThe revision label on the page was updated from v3.6.6 to v3.7.0. This indicates an updated edition of the study documents.SummaryDifference0.0%

- Check35 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, signaling a new build of the page. It likely reflects minor fixes or updates to the page rather than changes to the study data.SummaryDifference0.0%

- Check42 days agoChange DetectedA new line '2018 ( U.S. NIH Grant/Contract )' was added to the study's identifiers section. This records NIH funding information associated with the trial.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page now shows an updated revision label Revision: v3.6.5, and the Plain Language Summary section has been removed along with the older Revision: v3.6.4.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, reflecting a minor update to the page's version metadata rather than its content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.